Suchergebnisse - "O'Day, Steven J"

PubPharm (10)

1

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma : results from the CAPRA study

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Silk, A. | O'Day, S. | Kaufman, H. | +19

2

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

enthalten in: Journal for immunotherapy of cancer | 2023

von Rudin, C. | Pandha, H. | Zibelman, M. | +18

3

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical Trials

enthalten in: JAMA oncology | 2020

von Puzanov, I. | Ribas, A. | Robert, C. | +18

4

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

enthalten in: Journal for immunotherapy of cancer | 2020

von Arnaldez, F. | O'Day, S. | Drake, C. | +8

5

Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy

enthalten in: Clinical chemistry | 2020

von Lin, S. | Chang, S. | Lam, S. | +11

6

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States : An Expanded Access Program

enthalten in: Journal of immunotherapy (Hagerstown, Md. : 1997) | 2017

von Gangadhar, T. | Hwu, W. | Postow, M. | +14

7

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2015

von Ribas, A. | Puzanov, I. | Dummer, R. | +33

CommentIn: Lancet Oncol. 2015 Aug;16(8):873-4. - PMID 26115798

8

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma

enthalten in: Investigational new drugs | 2012

von O'Day, S. | Pavlick, A. | Albertini, M. | +7

9

BEAM : a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2012

von Kim, K. | Sosman, J. | Fruehauf, J. | +10

CommentIn: J Clin Oncol. 2012 Jan 1;30(1):6-7. - PMID 22124100

10

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) : a novel strategy for the treatment of melanoma and other malignancies

enthalten in: Cancer | 2007

von O'Day, S. | Hamid, O. | Urba, W.

1
[1]